There is disclosed a process for producing taurine in a molar yield of at least 80% from alkali isethionate, alkali ditaurinate, or alkali tritaurinate by adding excess ammonia and at least of equal molar amount of an alkali hydroxide to a solution comprised of alkali ditaurinate, alkali tritaurinate, or their mixture and subjecting the solution to an ammonolysis to yield a solution comprised of alkali taurinate.

There is disclosed a process for producing alkali taurinate by the ammonolysis of alkali ditaurinate, alkali tritaurinate, or a solution of alkali ditaurinate and alkali tritaurinate in the presence of one or more catalysts. The ammonolysis reaction is catalyzed by alkali salts of hydroxide, sulfate, sulfite, phosphate, or carbonate.

There is disclosed a process for producing alkali taurinate by the ammonolysis of alkali ditaurinate, alkali tritaurinate, or a solution of alkali ditaurinate and alkali tritaurinate in the presence of one or more catalysts. The ammonolysis reaction is catalyzed by alkali salts of hydroxide, sulfate, sulfite, phosphate, or carbonate.

There is disclosed a process for producing alkali taurinate by the ammonolysis of alkali ditaurinate, alkali tritaurinate, or a solution of alkali ditaurinate and alkali tritaurinate in the presence of one or more catalysts. The ammonolysis reaction is catalyzed by alkali salts of hydroxide, sulfate, sulfite, phosphate, or carbonate.

A method and production system for removing impurities from a taurine mother liquor and recovering the taurine mother liquor recovery. The method and system can be used in an ethylene oxide production process for taurine and the treatment of the last mother liquor of taurine. The last mother liquor of taurine is ion-exchanged through an anion exchange resin; then the anion exchange resin is eluted and regenerated with alkaline solution, and the outlet material liquor is collected; (b) the collected outlet material liquor is subjected to ammonia mixing treatment, and the mother liquor is generated after the impunity is removed and the separation of the solid and liquor; (c) the generated mother liquor is then returned to the ammonolysis step of taurine production. After the last mother liquor of taurine is treated by the anion exchange resin, more impurities in the last mother liquor can be removed, and salt is further removed by ammonia mixing treatment to generate a pure taurine mother liquor, thereby realizing the recovery of the mother liquor and improving the product yield.

A method and production system for removing impurities from a taurine mother liquor and recovering the taurine mother liquor recovery. The method and system can be used in an ethylene oxide production process for taurine and the treatment of the last mother liquor of taurine. The last mother liquor of taurine is ion-exchanged through an anion exchange resin; then the anion exchange resin is eluted and regenerated with alkaline solution, and the outlet material liquor is collected; (b) the collected outlet material liquor is subjected to ammonia mixing treatment, and the mother liquor is generated after the impunity is removed and the separation of the solid and liquor; (c) the generated mother liquor is then returned to the ammonolysis step of taurine production. After the last mother liquor of taurine is treated by the anion exchange resin, more impurities in the last mother liquor can be removed, and salt is further removed by ammonia mixing treatment to generate a pure taurine mother liquor, thereby realizing the recovery of the mother liquor and improving the product yield.

There is disclosed a process for producing taurine in a molar yield of at least 80% from alkali isethionate, alkali ditaurinate, or alkali tritaurinate by adding excess ammonia and at least of equal molar amount of an alkali hydroxide to a solution comprised of alkali ditaurinate, alkali tritaurinate, or their mixture and subjecting the solution to an ammonolysis to yield a solution comprised of alkali taurinate.

There is disclosed a process for producing taurine in a molar yield of at least 80% from alkali isethionate, alkali ditaurinate, or alkali tritaurinate by adding excess ammonia and at least of equal molar amount of an alkali hydroxide to a solution comprised of alkali ditaurinate, alkali tritaurinate, or their mixture and subjecting the solution to an ammonolysis to yield a solution comprised of alkali taurinate.

This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.

This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.